- Sanofi to mull riliprubart’s future after stopping late-stage nerve disease studySanofi is ending a Phase 3 trial of its antibody drug in a rare neurological disorder after an independent committee said the study was unlikely to show sufficient efficacy. The broader future of…Endpoints · 1mo ago↗ source
- Parabilis' $670M IPO sets new biotech record, will fund cancer drugDespite all the noise around massive upcoming IPOs for AI giants, a drug developer was able to attract enough investor interest to achieve the biggest Nasdaq debut the biopharma industry has ever s…Endpoints · 1mo ago↗ source
- Eli Lilly's claims data deadline may kick off new 340B fightEli Lilly’s deadline has passed for hospitals to comply with its new 340B claims data policy, and for now the pharma company is staying mum on its next steps. But just because Lilly is declining ...